Another upcoming clinical data catalyst for Access that is expected before year-end involves the Company's cobalamin (vitamin B12) based nanopolymer drug delivery system for the oral administration of large molecules such as insulin, human growth hormone (hGH), and erythropoietin (EPO) in preclinical animal models. This novel delivery mechanism utilizes the body's vitamin B12 absorption system in a Trojan Horse manner with the potential to eliminate the need for injections of widely used drugs such as insulin, hGH, and EPO.
A long-acting, basal insulin product (similar to the activity profile of Lantus insulin) is the most advanced in terms of achieving oral bioavailability of about 80-90% after initially achieving results in the 30-40% range, and Access previously announced in June that two bio-pharmaceutical companies are conducting preclinical studies to validate the Company’s results for a long-acting oral insulin product before entering formal licensing negotiations.
Access Pharma: Clinical and Commercial MuGard Updates -- Seeking Alpha
A long-acting, basal insulin product (similar to the activity profile of Lantus insulin) is the most advanced in terms of achieving oral bioavailability of about 80-90% after initially achieving results in the 30-40% range, and Access previously announced in June that two bio-pharmaceutical companies are conducting preclinical studies to validate the Company’s results for a long-acting oral insulin product before entering formal licensing negotiations.
Access Pharma: Clinical and Commercial MuGard Updates -- Seeking Alpha
